Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa

Journal of Antimicrobial Chemotherapy

Volumn 73, Issue 3, 2018, Pages 658-663

  Fraile Ribot, Pablo A ^a   Cabot, Gabriel ^a   Mulet, Xavier ^a   Periañez, Leonor ^a   Luisa Martin Pena M ^a   Juan, Carlos ^a   Pérez, José L ^a   Oliver, Antonio ^a  

^a HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AVIBACTAM PLUS CEFTAZIDIME; AZTREONAM; BACTERIAL ENZYME; BETA LACTAMASE; BETA LACTAMASE AMPC; BETA LACTAMASE OXA 14; CARBAPENEM; CEFEPIME; CEFTAZIDIME; CEFTOLOZANE PLUS TAZOBACTAM; CIPROFLOXACIN; COLISTIN; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TICARCILLIN; TOBRAMYCIN; UNCLASSIFIED DRUG; AMPC BETA-LACTAMASES; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; CEFTOLOZANE, TAZOBACTAM DRUG COMBINATION; CEPHALOSPORIN DERIVATIVE; TAZOBACTAM;

AMINO ACID SEQUENCE; AMPR GENE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL GENE; BACTERIAL GENOME; BACTERIUM ISOLATE; BETA-LACTAM RESISTANCE; BROTH DILUTION; CLONAL EVOLUTION; CLONE; COHORT ANALYSIS; GENE MUTATION; GENE OVEREXPRESSION; GENOME ANALYSIS; GENOTYPE; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MULTILOCUS SEQUENCE TYPING; MUTANT; NONHUMAN; OPRD GENE; PHENOTYPE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; WHOLE GENOME SEQUENCING; BACTERIUM IDENTIFICATION; DRUG EFFECT; GENETICS; HORIZONTAL GENE TRANSFER; MICROBIAL SENSITIVITY TEST;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BACTERIAL TYPING TECHNIQUES; BETA-LACTAMASES; CEPHALOSPORINS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GENE TRANSFER, HORIZONTAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MULTILOCUS SEQUENCE TYPING; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TAZOBACTAM;

EID: 85043341833     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkx424     Document Type: Article

References (23)

1. Livermore DM. Has the era of untreatable infections arrived? J Antimicrob Chemother 2009; 64 Suppl 1: i29-36.
2. Mesaros N, Nordmann P, Plésiat P et al. Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. Clin Microbiol Infect 2007; 13: 560-78.
3. Peña C, Suarez C, Gozalo M et al. Prospective multicenter study of the impact of carbapenem resistance on mortality in Pseudomonas aeruginosa bloodstream infections. Antimicrob Agents Chemother 2012; 56: 1265-72.
4. Lister PD, Wolter DJ, Hanson ND. Antibacterial-resistant Pseudomonas aeruginosa:clinical impact and complex regulation of chromosomally encoded resistancemechanisms. Clin Microbiol Rev 2009; 22: 582-610.
5. Poole K. Pseudomonas aeruginosa: resistance to the max. Front Microbiol 2011; 2: 65.
6. Woodford N, Turton JF, Livermore DM. Multiresistant Gram-negative bacteria:the role of high-risk clones in the dissemination of antibiotic resistance. FEMS Microbiol Rev 2011; 35: 736-55.
7. Oliver A, Mulet X, López-Causapé C et al. The increasing threat of Pseudomonas aeruginosa high-risk clones. Drug Resist Updat 2015; 21-22:41-59.
8. Moya B, Zamorano L, Juan C et al. Activity of a new cephalosporin, CXA-101 (FR264205), against β-lactam-resistant Pseudomonas aeruginosamutants selected in vitro and after antipseudomonal treatment of intensive care unit patients. Antimicrob Agents Chemother 2010; 54: 1213-7.
9. Torrens G, Cabot G, Ocampo-Sosa AA et al. Activity of ceftazidimeavibactam against clinical and isogenic laboratory Pseudomonas aeruginosa isolates expressing combinations of most relevant β-lactam resistance mechanisms. Antimicrob Agents Chemother 2016; 60: 6407-10.
10. van Duin D, Bonomo RA. Ceftazidime/avibactam and ceftolozane/tazobactam:second-generation β-lactam/b-lactamase inhibitor combinations. Clin Infect Dis 2016; 63: 234-41.
11. Cabot G, Bruchmann S, Mulet X et al. Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC. Antimicrob Agents Chemother 2014; 58: 3091-9.
12. Haidar G, Philips NJ, Shields RK et al. Ceftolozane-tazobactam for the treatment ofmultidrug-resistant Pseudomonas aeruginosa infections: clinical effectiveness and evolution of resistance. Clin Infect Dis 2017; 65: 110-20.
13. Cabot G, Ocampo-Sosa AA, Domínguez MA et al. Genetic markers of widespread extensively drug-resistant Pseudomonas aeruginosa high-risk clones. Antimicrob Agents Chemother 2012; 56: 6349-57.
14. Cabot G, Ocampo-Sosa AA, Tubau F et al. Overexpression of AmpC and efflux pumps in Pseudomonas aeruginosa isolates from bloodstream infections:prevalence and impact on resistance in a Spanish multicenter study Antimicrob Agents Chemother 2011; 55: 1906-11.
15. Cabot G, López-Causapé C, Ocampo-Sosa AA et al. Deciphering the resistome of the widespread Pseudomonas aeruginosa sequence type 175 international high-risk clone through whole-genome sequencing. Antimicrob Agents Chemother 2016; 60: 7415-23.
16. Cholley P, Thouverez M, Hocquet D et al. Most multidrug-resistant Pseudomonas aeruginosa isolates from hospitals in eastern France belong to a few clonal types. JClinMicrobiol 2011; 49: 2578-83.
17. Berrazeg M, Jeannot K, Ntsogo Enguéné VY et al. Mutations in β-lactamase AmpC increase resistance of Pseudomonas aeruginosa isolates to antipseudomonal cephalosporins. Antimicrob Agents Chemother 2015; 59: 6248-55.
18. Nordmann P, Mammeri H. Extended-spectrum cephalosporinases:structure, detection and epidemiology. Future Microbiol 2007; 2: 297-307.
19. Danel F, Hall LMC, Gur D et al. OXA-14, another extended-spectrum variant of OXA-10 (PSE-2) β-lactamase from Pseudomonas aeruginosa. Antimicrobial Agents Chemother 1995; 39: 1881-4.
20. Juan C, Zamorano L, Pérez JL et al. Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains. Antimicrob Agents Chemother 2010; 54: 846-51.
21. Livermore DM, Mushtaq S, Ge Y et al. Activity of cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa and Burkholderia cepacia group strains and isolates. Int J Antimicrob Agents 2009; 34: 402-6.
22. Fraile-Ribot PA, Mulet X, Cabot G et al. In vivo emergence of resistance to novel cephalosporin-β-lactamase inhibitor combinations through the duplication of the amino acid D149 from OXA-2 β-lactamase (OXA-539) in sequence type 235 Pseudomonas aeruginosa. Antimicrob Agents Chemother 2017; 61: e01117-17.
23. Evans BA, Amyes SG. OXA β-lactamases. Clin Microbiol Rev 2014; 27: 241-63.